Founded as a digitally native, direct-to-consumer brand, bioClarity will use the funding to accelerate its growth through larger marketing initiatives and additional product innovation. Prolog Ventures, a venture capital firm that backs early-stage, high-growth health and wellness companies, invested $6 million to lead the round, which also included the existing investors.
“Today’s consumers seek skincare and wellness products formulated with healthy, plant-based, clinically effective ingredients,” said Rick Sliter, president and CEO of bioClarity. “I believe our unique offerings and deep understanding of our customers’ needs, wants, and lifestyles have led to our rapid growth since we first launched our initial product line approximately two years ago.”
Here’s the context: As the health-conscious millennial and Gen Z consumer continues to look for natural, yet powerful skincare products, the brand has expanded from its initial offering, the Clear Skin Routine, to a full line of unique regimen-based and mix-and-match plant-based skincare products.
The full product assortment now includes two additional skincare routines, face masques, a serum, body wash and beauty supplement.
All of bioClarity’s products contain wholesome ingredients such as the brand’s patented Floralux®, a deeply nourishing form of chlorophyll that’s both an antioxidant and clinically proven to help reduce the appearance of redness and pore size. Additionally, all bioClarity products are vegan, cruelty-free and made without parabens, sulfates and phthalates.
“Personal care is a key area of focus for Prolog, and we are very excited to partner with the bioClarity team, a dynamic and experienced group of entrepreneurs building a brand that has seen great momentum in a very short period,” said Rob Rosenberg, Partner with Prolog Ventures. “The brand’s promise is rare and powerful – you can have skincare products featuring a unique patented ingredient that is clinically validated to work well, and yet is also plant-based, gentle, and reasonably priced.”